Merck & Co Inc $58.58

up +0.03


10/7/2014 04:00 PM  |  NYSE : MRK  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get MRK Trend Analysis - it has outperformed the S&P 500 by 4%

Partner Headlines

  1. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  2. Job or Invest: Growth Often Equals Happiness

    YCharts
  3. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  4. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  5. Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline

    Benzinga
  6. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  7. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  8. US Stock Futures Fall Ahead Of Home Sales Report

    Benzinga
  9. Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly

    Benzinga
  10. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  11. Achillion

    IBD
  12. Dow, S&P 500 End At New Highs, Led By Auto Retailers

    IBD
  13. Achillion Could Win Idenix's Mystery Suitor: Analyst

    IBD
  14. Dow, S&P 500 Hit All-Time Highs As Volume Swells

    IBD
  15. 5-Star Biotech Stock Watch: Synta Pharmaceuticals

    Benzinga
  16. Stock Futures Hold Narrow Gains; Adobe Systems Up On Q2 Results

    IBD
  17. Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry

    IBD
  18. Achillion Gets Massive Price Target Hike On HCV Drugs

    IBD
  19. Achillion Gets Massive Price Target Hike On HCV Drugs

    IBD
  20. U.S. Equity Markets Continue to Hit New Highs

    GuruFocus
  21. UPDATE: Bank Of America Reiterates On Merck & Co. On Higher Sales Estimates

    Benzinga
  22. Feed Your Brain Daily: Read, Study, Mingle

    IBD
  23. Sovaldi and Drug Pricing: The United States of Saps

    YCharts
  24. FDA lifts hold, Achillion soars

    IBD
  25. ETF Outlook For Tuesday, June 10, 2014 (IAT, FXE, PBE, HYHG, IDIX, MRK)

    Benzinga
  26. Achillion Forges Ahead With Hep C Program On FDA OK

    IBD
  27. Merck Makes Big Hep C Buy

    IBD
  28. Benzinga's M&A Chatter for Monday June 9, 2014

    Benzinga
  29. Market Wrap For June 9: Markets Higher On St. Louis Fed Comments, Low Volume

    Benzinga
  30. Stocks Gain In Mixed Trade; Chips Soar, Keurig Caves

    IBD
  31. Mid-Afternoon Market Update; Icahn's 9% Stake In Family Dollar, Tyson Foods ...

    Benzinga
  32. Are Gilead Shares Overreacting To Merck's Idenix Acquisition?

    Benzinga
  33. Tyson's $8.5 Bil Hillshire Deal Tops Monday's M&As

    IBD
  34. Mid-Day Market Update: Idenix Pharma Surges On Merck Buyout; Pilgrim's ...

    Benzinga
  35. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  36. Benzinga's Volume Movers

    Benzinga
  37. Stocks Hitting 52-Week Highs

    Benzinga
  38. Mid-Morning Market Update: Markets Edge Higher; Tyson Wins Bidding Battle ...

    Benzinga
  39. Morning Market Movers

    Benzinga
  40. Hepatitis C Stocks Move After Idenix Rockets Up 235%

    Benzinga
  41. Benzinga's Top #PreMarket Losers

    Benzinga
  42. Benzinga's Top #PreMarket Gainers

    Benzinga
  43. UPDATE: Merck Announces Will Purchase Idenix for $3.85Bn

    Benzinga
  44. Stocks Poised to Slip from Record Highs

    FoxBusiness
  45. Wall Street Turns Higher

    FoxBusiness
  46. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  47. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  48. R&D Tax Credit Passed In The House, Faces Challenges Ahead

    Benzinga
  49. Merck inks $600 mil-plus deal

    IBD
  50. Merck Sells Japan Eye-Treatment Rights

    FoxBusiness
Trading Center